| Biomarker ID | 1249 |
| PMID | 24255071 |
| Year | 2013 |
| Biomarker | Lactate Dehydrogenase [LDH] |
| Biomarker Basis | Concentration Based (U/L) |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: [2.68 (95% CI: 1.72–4.18)] Multivariate Analysis: [1.75 (95% CI: 1.08–2.82)] |
| Effect on Pathways | Pathways include: TRXA, RPLF, CLPP, PRS, RPOB |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 201 patients with Prostate cancer were defined as the cohort. They were randomised into 134 tasquinimod and 67 placebo arms. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p < 0.001; Multivariate: p =0.023 |
| Method Used | Assays |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | NCT00560482 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |